BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 35086552)

  • 1. SF3B1 inhibition disrupts malignancy and prolongs survival in glioblastoma patients through BCL2L1 splicing and mTOR/ß-catenin pathways imbalances.
    Fuentes-Fayos AC; Pérez-Gómez JM; G-García ME; Jiménez-Vacas JM; Blanco-Acevedo C; Sánchez-Sánchez R; Solivera J; Breunig JJ; Gahete MD; Castaño JP; Luque RM
    J Exp Clin Cancer Res; 2022 Jan; 41(1):39. PubMed ID: 35086552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Splicing factor SF3B1 is overexpressed and implicated in the aggressiveness and survival of hepatocellular carcinoma.
    López-Cánovas JL; Del Rio-Moreno M; García-Fernandez H; Jiménez-Vacas JM; Moreno-Montilla MT; Sánchez-Frias ME; Amado V; L-López F; Fondevila MF; Ciria R; Gómez-Luque I; Briceño J; Nogueiras R; de la Mata M; Castaño JP; Rodriguez-Perálvarez M; Luque RM; Gahete MD
    Cancer Lett; 2021 Jan; 496():72-83. PubMed ID: 33038489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spliceosome component SF3B1 as novel prognostic biomarker and therapeutic target for prostate cancer.
    Jiménez-Vacas JM; Herrero-Aguayo V; Gómez-Gómez E; León-González AJ; Sáez-Martínez P; Alors-Pérez E; Fuentes-Fayos AC; Martínez-López A; Sánchez-Sánchez R; González-Serrano T; López-Ruiz DJ; Requena-Tapia MJ; Castaño JP; Gahete MD; Luque RM
    Transl Res; 2019 Oct; 212():89-103. PubMed ID: 31344348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug.
    Alors-Perez E; Blázquez-Encinas R; Alcalá S; Viyuela-García C; Pedraza-Arevalo S; Herrero-Aguayo V; Jiménez-Vacas JM; Mafficini A; Sánchez-Frías ME; Cano MT; Abollo-Jiménez F; Marín-Sanz JA; Cabezas-Sainz P; Lawlor RT; Luchini C; Sánchez L; Sánchez-Hidalgo JM; Ventura S; Martin-Hijano L; Gahete MD; Scarpa A; Arjona-Sánchez Á; Ibáñez-Costa A; Sainz B; Luque RM; Castaño JP
    J Exp Clin Cancer Res; 2021 Dec; 40(1):382. PubMed ID: 34857016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of Splicing Factor 3b Subunit 1 (SF3B1) Reduced Cell Proliferation, Induced Apoptosis and Resulted in Cell Cycle Arrest by Regulating Homeobox A10 (HOXA10) Splicing in AGS and MKN28 Human Gastric Cancer Cells.
    Zhang Y; Yuan Z; Jiang Y; Shen R; Gu M; Xu W; Gu X
    Med Sci Monit; 2020 Jan; 26():e919460. PubMed ID: 31927557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Splicing machinery dysregulation drives glioblastoma development/aggressiveness: oncogenic role of SRSF3.
    Fuentes-Fayos AC; Vázquez-Borrego MC; Jiménez-Vacas JM; Bejarano L; Pedraza-Arévalo S; L-López F; Blanco-Acevedo C; Sánchez-Sánchez R; Reyes O; Ventura S; Solivera J; Breunig JJ; Blasco MA; Gahete MD; Castaño JP; Luque RM
    Brain; 2020 Dec; 143(11):3273-3293. PubMed ID: 33141183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Knockdown of SF3B1 inhibits cell proliferation, invasion and migration triggering apoptosis in breast cancer via aberrant splicing.
    Zhang L; Zhang X; Zhang H; Liu F; Bi Y; Zhang Y; Cheng C; Liu J
    Breast Cancer; 2020 May; 27(3):464-476. PubMed ID: 31919642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma.
    Sciarrillo R; Wojtuszkiewicz A; El Hassouni B; Funel N; Gandellini P; Lagerweij T; Buonamici S; Blijlevens M; Zeeuw van der Laan EA; Zaffaroni N; Deraco M; Kusamura S; Würdinger T; Peters GJ; Molthoff CFM; Jansen G; Kaspers GJL; Cloos J; Giovannetti E
    EBioMedicine; 2019 Jan; 39():215-225. PubMed ID: 30581150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The SF3B1
    Guo J; Li C; Fang Q; Liu Y; Wang D; Chen Y; Xie W; Zhang Y
    J Exp Clin Cancer Res; 2022 Jan; 41(1):26. PubMed ID: 35039052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring Splicing Modulation as an Innovative Approach to Combat Pancreatic Cancer: SF3B1 Emerges as a Prognostic Indicator and Therapeutic Target.
    Sciarrillo R; Terrana F; Comandatore A; Supadmanaba IGP; Wang B; Hassouni BE; Mantini G; Jansen G; Avan A; Carbone D; Diana P; Peters GJ; Morelli L; Cloos J; Assaraf YG; Giovannetti E
    Int J Biol Sci; 2024; 20(8):3173-3184. PubMed ID: 38904016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of SF3B1 in the pre-mRNA spliceosome induces a RIG-I-dependent type I IFN response.
    Chang AY; Zhou YJ; Iyengar S; Pobiarzyn PW; Tishchenko P; Shah KM; Wheeler H; Wang YM; Loria PM; Loganzo F; Woo SR
    J Biol Chem; 2021 Nov; 297(5):101277. PubMed ID: 34619148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of SF3b1 by pladienolide B evokes cycle arrest, apoptosis induction and p73 splicing in human cervical carcinoma cells.
    Zhang Q; Di C; Yan J; Wang F; Qu T; Wang Y; Chen Y; Zhang X; Liu Y; Yang H; Zhang H
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):1273-1280. PubMed ID: 30963795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations.
    Choudhary GS; Pellagatti A; Agianian B; Smith MA; Bhagat TD; Gordon-Mitchell S; Sahu S; Pandey S; Shah N; Aluri S; Aggarwal R; Aminov S; Schwartz L; Steeples V; Booher RN; Ramachandra M; Samson M; Carbajal M; Pradhan K; Bowman TV; Pillai MM; Will B; Wickrema A; Shastri A; Bradley RK; Martell RE; Steidl UG; Gavathiotis E; Boultwood J; Starczynowski DT; Verma A
    Elife; 2022 Aug; 11():. PubMed ID: 36040792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metformin and simvastatin exert additive antitumour effects in glioblastoma via senescence-state: clinical and translational evidence.
    Fuentes-Fayos AC; G-García ME; Pérez-Gómez JM; Montero-Hidalgo AJ; Martín-Colom J; Doval-Rosa C; Blanco-Acevedo C; Torres E; Toledano-Delgado Á; Sánchez-Sánchez R; Peralbo-Santaella E; Ortega-Salas RM; Jiménez-Vacas JM; Tena-Sempere M; López M; Castaño JP; Gahete MD; Solivera J; Luque RM
    EBioMedicine; 2023 Apr; 90():104484. PubMed ID: 36907105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Jerantinine A induces tumor-specific cell death through modulation of splicing factor 3b subunit 1 (SF3B1).
    Chung FF; Tan PF; Raja VJ; Tan BS; Lim KH; Kam TS; Hii LW; Tan SH; See SJ; Tan YF; Wong LZ; Yam WK; Mai CW; Bradshaw TD; Leong CO
    Sci Rep; 2017 Feb; 7():42504. PubMed ID: 28198434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Splicing factor SF3B1 promotes endometrial cancer progression via regulating KSR2 RNA maturation.
    Popli P; Richters MM; Chadchan SB; Kim TH; Tycksen E; Griffith O; Thaker PH; Griffith M; Kommagani R
    Cell Death Dis; 2020 Oct; 11(10):842. PubMed ID: 33040078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatostatin Receptor Splicing Variant
    Fuentes-Fayos AC; G-García ME; Pérez-Gómez JM; Peel A; Blanco-Acevedo C; Solivera J; Ibáñez-Costa A; Gahete MD; Castaño JP; Luque RM
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MSK1-Mediated β-Catenin Phosphorylation Confers Resistance to PI3K/mTOR Inhibitors in Glioblastoma.
    Wu S; Wang S; Zheng S; Verhaak R; Koul D; Yung WK
    Mol Cancer Ther; 2016 Jul; 15(7):1656-68. PubMed ID: 27196759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SF3B3-regulated mTOR alternative splicing promotes colorectal cancer progression and metastasis.
    Xu T; Li X; Zhao W; Wang X; Jin L; Feng Z; Li H; Zhang M; Tian Y; Hu G; Yue Y; Dai X; Shan C; Zhang W; Zhang C; Zhang Y
    J Exp Clin Cancer Res; 2024 Apr; 43(1):126. PubMed ID: 38671459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SF3B1 is a stress-sensitive splicing factor that regulates both HSF1 concentration and activity.
    Kim Guisbert KS; Guisbert E
    PLoS One; 2017; 12(4):e0176382. PubMed ID: 28445500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.